Corbus Pharmaceuticals reported on December 11, 2025, positive results from its Phase 1a study on oral CRB-913, an obesity management drug, indicating significant weight loss in participants with an average 2.9% placebo-adjusted reduction by Day 14. The study demonstrated safety with no serious adverse effects and stable neuropsychiatric assessments.